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High-risk human papillomavirus (HR-HPV) persistent infection is responsible for the development of the
majority of cervical cancers. The therapy against HPV-associated cancer requires knowledge of the viral
gene expression mechanisms. In this study, the polyadenylated polycistronic transcripts containing full-
size E1ORF and produced from the early P14 promoter were detected for the ﬁrst time in cervical tumors
with episomal forms of the HPV16 genome. P14-initiated mRNAs were revealed also in precancerous
lesions. The amount of P14-initiated transcripts was signiﬁcantly less compared to transcripts initiated
from the major P97 HPV16 promoter in cervical intraepithelial neoplasms and squamous cell carcinomas.
The ratios of P97/P14-transcripts determined by qRT-PCR were unique for each clinical sample and varied
in quite wide ranges independent of disease progression stages or tumor grade. These data suggest that
the levels of P14- and P97-transcripts are regulated independently from each other in cervical neo-
plasms.
& 2015 Elsevier Inc. All rights reserved.Introduction
Persistent infection by high-risk human papillomavirus (HR-HPV)
causes the development of the majority of cervical cancers, many
other anogenital tumors, and 25–30% of oropharyngeal cancers (zur
Hausen, 2009). HPV type 16 (HPV16) is the most prevalent HR-HPV
found in human cervical cancers (Psyrri and DiMaio, 2008; Samoylova
et al., 1995). The development of therapy against persistent HR-HPV
infection, cervical intraepithelial neoplasia (CIN) and invasive cancer
requires knowledge of mechanisms of the viral replication and the
regulation of viral genes expression at these stages of disease pro-
gression. Papillomaviruses are small DNA viruses with a circular
double stranded DNA genome that is replicated episomally in the
nuclei of infected cells and may be integrated in the host cell DNA
during cancerogenic progression. HPV genomes typically encode early
(E) and late (L) genes that are tightly regulated at the level of tran-
scription and RNA splicing. Sequential expression of early and late
genes is strictly linked to the differentiation state of the infected cell
(for rev. see Bodily (2011)).x.ru (M. Fedorova),
yndex.ru (N. Kisseljova).DNA replication requires two early viral proteins that both interact
with viral origin of replication (ori): the DNA helicase E1 and the
sequence-speciﬁc transcriptional activator E2 (Hebner and Laimins,
2006). The E1 protein serves as a replication initiator, promoting ori
unwinding (Bergvall et al., 2013). E1 protein activity in replication has
been studied in cell models, but relatively little is known about reg-
ulation of the HPV E1 gene transcription. Recently it has been
demonstrated in the model system reﬂecting only early stages of the
papillomavirus infection cycle that E1 protein expression and ampli-
ﬁcation of the HPV-16 genome require a polycistronic, spliced within
E6 gene mRNA. This RNA initiates at a novel TATAA dependent pro-
moter (P14) upstream of promoter P97 with a start site at nucleotide
(nt) 14 (Lace et al., 2008). The major early HPV-16 promoter, P97, was
not responsible for E1 production because mutations inactivating P97
did not affect the initial HPV-16 plasmid synthesis in comple-
mentation assay. The corresponding transcript in HPV18, grown
in vitro in raft cultures, has recently been identiﬁed (Wang
et al., 2011).
Detectable transcription of only some fragments of the HPV16
E1 region was demonstrated by different techniques in cervical
precancerous lesions and carcinomas (Chen et al., 2014; Coupe
et al., 2012; Schmitt et al., 2010). Up to now mRNA that is found to
be required for translation of functional E1 protein in model sys-
tem has been mapped neither in naturally infected cells nor in HR-
HPV-associated tumors, possibly due to their very low levels.
Fig. 1. Analysis of E1 mRNA in cervical carcinomas by RT-PCR. A. Genetic and transcriptional map of HPV16 and localization of analyzed PCR products. The early region of
HPV16 genome is depicted by a hairline with a scale in base pairs. Location of early gene ORFs in HPV16 genome are depicted by boxes. URR-upstream regulator region. Poly-
A, position of polyadenilation site. The exons and introns are indicated by black rectangles and black lines, respectively. The numbers printed below the lines indicate the
splice junction positions. The positions of E1 RT-PCR products are indicated by horizontal lines and enumerated (1–5). B,C. Analysis of E1 RT-PCR products (1–5, second
round) in agarose gel electrophoresis. cDNAs were prepared using oligo(dT) primer; RT (–), cDNA preparation without reverse transcriptase, a control of genome DNA
contamination; M, molecular marker, 100 bp ladder (SibEnzyme, Russia). B. Samples of tumors (T) with episomal forms of HPV16 DNA; C. Samples of tumors (T) with
integrated forms of HPV16 DNA and partial deletion of E1 gene, negative control. Representative experiments are presented.
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encoding functional E1 protein in cervical carcinomas of different
stages with episomal state of the HPV16 of genome. We also have
demonstrated the usage of new P14 promoter for early gene tran-
scription along with the major P97 promoter and observed that the
level of P14-initiated transcripts was signiﬁcantly less than those of
transcripts initiated at P97 promoter in tumors as well as in advanced
cervical intraepithelial neoplasia (CIN 2, 3 stages).Results
Analysis of HPV16 E1 transcripts in cervical SCCs
To identify polyadenylated E1 mRNA in tumors with episomal
HPV16 genome we produced the ﬁrst-strand cDNA using an oligo
(dT) primer (Fig. 1A). As with the earlier attempts we were unable
to successfully amplify cDNA sequences across the entire E1ORF in
the ﬁrst round of PCR. Then to conﬁrm that the full-size E1ORF was
transcribed we used overlapping sets of PCR primers in the second
round of PCR. We revealed PCR products in ﬁve overlapping regions
in all 13 samples with episomal forms of the HPV16 DNA (Table 1,
Fig. 1B). The identity of PCR products of each region to HPV16 E1
sequences were conﬁrmed by cloning and sequencing. The PCR
products overlapping full-size E1 ORF were absent in tumors with
partly deleted E1 gene as a result of HPV genome integration into
cell DNA (Fig. 1C). These results demonstrate the presence of
polyadenylated polycistronic mRNAs containing complete E1 ORF
and also E7, E2, E1^E4 and E5 ORFs in SCCs at very low levels.Analysis of early transcription start sites in cervical SCCs and CINs
To determined TSS of the E1 mRNA we produced the ﬁrst-
strand cDNA using E1-speciﬁc primers (R1) and total RNAs from
SCCs (Fig. 2A and B). These cDNAs were ampliﬁed with forward
primers F2 located two nucleotides downstream of the promoter
P14. Three types of E1 transcripts were detected in the carcinomas
with different ratio of splice variants in different samples (Fig. 2B).
None of transcripts were revealed when control F1 primer located
immediately upstream of P14 was used. Splice variants were
conﬁrmed by sequencing (Supplementary Fig. 1). P14 transcript
spliced in E6 (226/409 nt) that was found to be required for
translation of E1 protein in vitro were revealed in all analyzed
cases (Lace et al., 2008). The splicing variants 226/526 and
unspliced transcripts were not detected in some cases. The func-
tionality of these transcripts is not yet clearly understood. We
demonstrated the presence of the E1-speciﬁc spliced in E6 gene
transcripts produced from P14 in the carcinomas in which mRNAs
with complete E1ORF were also revealed (Fig. 1B, Table 1). Thus
polyadenylated mRNAs containing complete E1 ORF, speciﬁcally
spliced within E6 gene (226/409) and produced from P14 pro-
moter are generated in cervical SCC (Lace et al., 2008).
To analyze the activity of P14 promoter in CINs PCR with the
same primers was done using the ﬁrst-strand cDNAs produced
from random hexaprimers (Fig. 2C, Table 1). In general, 226/409
spliced P14 transcripts were detected in 23 samples of CIN 2 and 3.
The results demonstrate that the usage of P14 promoter for early
gene transcription is common future of cervical SCCs and CINs.
Fig. 2. Analysis of early gene transcription start sites in CIN and cervical carcinomas by RT-PCR. A. Diagram of HPV16 mRNA species. All designations are indicated as in the
legend of Fig. 1. The positions of two TSS and RT-PCR primers are indicated by the broken arrows and horizontal arrows, respectively. Different splice variants within E6 gene
are denoted by checkmark, rhombs, and circles. The encoding potential indicates the early proteins which could be translated from a given mRNA. B, C. Analysis of RT-PCR
products in agarose gel electrophoresis. K–positive control, ampliﬁcation of HPV16 genome DNA; NK, negative control, PCR with F1 as forward primer; T–tumors, C, CIN. B.
cDNAs were prepared using E1-speciﬁc primer R1. C. cDNAs were prepared using random hexaprimers.
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To evaluate the P14 promoter activity we compared the quan-
tities of P14 transcripts and transcripts produced from early strong
P97 promoter by TaqMan qRT-PCR in the samples with the avail-
able amount of cDNA (Table 1). The number of P14 transcripts was
less than that initiated at P97 promoters in all tumors and in CINs
excluding one CIN 2 sample (C2) and one tumor (T14) where the
P97/P14 transcripts ratios were approximately equal to 1. The
levels of transcription from both promoters broadly varied from
sample to sample of CINs and tumors (from hundreds to hundreds
of thousands copies) that in particular may be a result of different
HPV genome copy numbers. Differences between copy numbers of
two types of transcripts were statistically signiﬁcant for all sample
groups (CIN2, CIN3 and SCCs, P 0.0147, 0.286 and 0.0166 respec-
tively, Fig. 3). The value of P97/P14 transcripts ratio is unique for
each sample and varies in quite wide ranges (from 2.6 to several
hundreds) independently on stages of disease progression or
tumor differentiation grade (Table 1). We have not revealed sig-
niﬁcant correlation between the P97/P14 transcripts ratios and
HPV DNA levels. In general P14 transcripts were revealed in 23
CINs and 14 SCC with episomal forms of HPV genome by gel
electrophoreses or qPCR analyses.Discussion
The full-length E1 protein of papillomaviruses is required for
the replication of viral DNA. It has been assumed earlier that
HPV16 E1 mRNA initiates at the major early P97 promoter and
arises through differential splicing in a fashion
similar to that of the E7 mRNA (for rev. see Zheng and Baker
(2006)). In this study we have demonstrated that thepolyadenylated polycistronic transcripts produced from P14 pro-
moter that contained the full-size E1 ORF are present in HPV16-
positive cervical carcinomas with episomal state of the viral gen-
ome persistence. These transcripts had different splice variants
within the E6 ORF (Fig. 2B, Supplementary Fig. 1). The transcripts
with splice donor site SD226 and the splice acceptor site SA409
that have been found to be required for E1 translation in model
system are detected in all analyzed samples (Lace et al., 2008).
Although this transcript not always was presented at abundant
levels compared to the other splicing forms. Coding potential of
two additional splice variants presented in only some SCC samples
is elusive. These ﬁnding suggest that E1 protein expression could
be regulated at the level of mRNA splicing within E6 gene by
unknown mechanism. At the same time, apparently P14 E1 tran-
script does not serve as a source for generation of mRNAs coding
all other early genes through differential splicing. It is well
established that the P97 promoter is responsible for almost all
early gene transcripts (at least 14 species of mRNA transcripts with
different variants of slicing in E1 ORF and various coding potential)
(for rev. see Zheng and Baker (2006)). Thus these data suggest that
the level of E1 protein expression may be independent from
mechanisms that determine alternative splicing of mRNAs of other
early genes. Although it can not be excluded that some minor
species of early gene mRNAs may be produced from P14
transcripts.
The presence E1 mRNAs not only in advanced CINs but in the
SCCs of different clinical stage serves as an indirect evidence
supporting the recent observation for a the new role of E1 HPV18
in cellular processes other than in viral replication (Castillo
et al., 2014).
We demonstrated the employment of recently discovered
promoter P14 at different stages of cervical tumor progression
from CIN2 to SCCs of different stages (Table 1). We revealed that
Fig. 3. Analysis of levels of transcription from P14 and P97 promoters by RT-qPCR.
The box plots of absolute numbers of P14 and P97 transcripts determined in equal
aliquots of RNA of each sample are presented. Medians, 25th and 75th percentiles
are indicated. P values are calculated by Mann–Whitney U test.
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niﬁcantly less than those of transcripts initiated at P97 promoters
in advanced cervical intraepithelial neoplasia (CIN 2, 3 stages) and
tumors. The low level of P14 transcription is the ﬁrst but appar-
ently not single reason of the extremely low concentration of E1-
speciﬁc mRNA in cells containing the HPV16 genome. The value of
P97/p14 transcripts ratio is unique for each clinical sample and
varies in quite wide ranges independently on stages of disease
progression or tumor grade. This data suggest that the levels of
two types of early transcripts are regulated/deregulated indepen-
dently from each other. Little is known about the interplay of these
promoters also it was shown in vitro that the activity of P14 and
P97 may be modulated by the same trans-acting cellular and viral
factors (Lace et al., 2008). Mechanisms determining differential
regulation of two early promoters remain to be elucidated.Conclusion
mRNA with coding potential for the functional HPV16 E1 pro-
tein was observed in clinical samples of cervical intraepithelial
neoplasia reﬂecting the early steps of papillomavirus infections
and in invasive cervical tumors. For the ﬁrst time employment of
P14 promoter for HPV16 early gene transcription simultaneously
with major P97 promoter was demonstrated in clinical samples.These ﬁndings are of interest to understand the mechanism of
viral mRNAs transcription in naturally infected cells and HPV-
associated tumors.Notes
All authors revised and approved the ﬁnal manuscript.Potential conﬂicts of interest
The authors declare no conﬂict of interest.Materials and methods
Clinical samples
CIN 2 and CIN 3 (23 samples) and squamous cell carcinomas
(SCC) of uterine cervix (16 samples) were obtained from patients
attending the N.N. Blokhin Russian Cancer Research Center. All
SCCs contained episomal forms of the HPV16 genome and two SCC
with integrated HPV16 were included as negative control (Table 1).
All tissues were collected under the approval of the Ethical Board
of the N.N. Blokhin Russian Cancer Research Center. Informed
consent was obtained from all patients.
RNA and DNA isolation
DNAs and RNAs were isolated from frozen tumor tissues by
homogenization in 4.5 M guanidine isothiocyanate and cen-
trifugation through cesium chloride cushion as described pre-
viously (Katargin et al., 2009). RNAs from precancerous lesions
(CIN) were isolated using a RNA isolation kit (RNA queos–4PCR,
Ambion, USA) as recommended by the supplier.
Determination of the physical state of HPV16 in SCC
The physical state of the viral genomes was analyzed using the
APOT assay, a 30-RACE PCR assay that allows differentiate episome-
derived transcripts from integrate-derived transcripts (Klaes et al.,
1999). The presence of HPV episomes in samples was conﬁrmed by
DNA PCR with the primers speciﬁc to full-size E2 ORF.
Reverse transcription and PCR ampliﬁcation of E1 sequence
Total RNA (1 μg) was reverse transcribed using an oligo(dT) 17-
primer coupled to a linker sequence (Frohman, 1993) and the
Moloney murine leukemia virus reverse transcriptase (Super
Script II RT, Invitrogen, USA) for 1 h at 42 °C in a ﬁnal volume of
20 ml. First-strand cDNAs encompassing viral E1 gene and 30 end of
E7 gene were subsequently ampliﬁed by PCR using HPV 16 E7-
speciﬁc primer as forward primer and linker-speciﬁc primer as the
reverse primer and Taq DNA Polymerase (Clontech, USA). The
ampliﬁcation product was used as template for nested PCR using
5 sets of E1-speciﬁc primers (Fig. 1A). All primer sequences and
PCR conditions used in this work are available upon request. An
additional DNase treatment step (Deoxyribonuсlease I Ampliﬁca-
tion Grade, Invitrogen, USA) was included for all RNA samples, and
DNA contamination was controlled by conducting cDNA prepara-
tion without reverse transcriptase for each RNA sample. To control
RNA integrity, ﬁrst-strand cDNA quality and quantity, PCR reac-
tions using HPRT-speciﬁc primers were performed in each sample.
To avoid samples cross contamination negative control was
included in each reaction and all reactions were repeated twice in
Table 1
Analysis of transcription from HPV16 early promoters.
Sample No. Clinical stage Tumor
graden
Status of HPV16 genome Presence of Е1 ORF Transcription from P14
Presence of P14 transcriptsnn Ratio of Р97/Р14
transcriptsnnn
C 1 cin2  n/t n/t þ 2,6
C 2 cin2  n/t n/t þ 1,4
C 3 cin2  n/t n/t þ 13,8
C 4 cin2  n/t n/t þ n/t
C 5 cin2  n/t n/t þ 72,0
C 6 cin2  n/t n/t þ 142,0
C 7 cin2  n/t n/t þ n/t
C 8 cin2  n/t n/t þ n/t
C 9 cin2  n/t n/t þ n/t
C 10 cin3  n/t n/t þ 47,3
C 11 cin3  n/t n/t þ 727,8
C 12 cin3  n/t n/t þ 555,2
C 13 cin3  n/t n/t þ 7,6
C 14 cin3  n/t n/t þ n/t
C 15 cin3  n/t n/t þ n/t
C 16 cin3  n/t n/t þ n/t
C 17 cin3  n/t n/t þ n/t
C 18 cin3  n/t n/t þ n/t
C 19 cin3  n/t n/t þ n/t
C 20 cin3  n/t n/t þ n/t
C 21 cin3  n/t n/t þ n/t
C 22 cin3  n/t n/t þ n/t
C 23 cin3  n/t n/t þ n/t
T 1 2 G2 ep þ þ n/t
T 2 3 G1 ep þ þ 101,3
T 3 1 G2 ep þ þ 77,0
T 4 2 G1 ep þ þ 30,8
T 5 3 G2 ep þ þ 14,0
T 6 1 G3 ep þ þ 19,0
T 7 2 G1 ep þ þ n/t
T 8 3 G2 ep þ þ 3,3
T 9 2 G1 ep þ þ 4,3
T 10 2 G1 ep þ þ 3,4
T 11 1 G1 ep þ þ 6,3
T 12 1 G2 ep n/t n/t 17,0
T 13 3 G2 ep þ þ n/t
T 14 1 G1 ep þ n/t 0,9
T 15 2 GX int  n/t n/t
T 16 3 G2 int  þ n/t
n/t – an experiment is not performed.
n tumor differentiation grade: G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; GX, grade of differentiation cannot be assessed; C, CIN,
cervical intraepithelial neoplasia grade 2 and 3; T, squamous cell carcinoma; ep, episomal form; int, integrated form.
nn analysis of P14 226^409 transcripts by RT-PCR and gel electrophoreses.
nnn analysis of P14 and P97 transcripts by RT-qPCR.
M. Fedorova et al. / Virology 488 (2016) 196–201200independent experiments. PCR products were analyzed by agarose
gel electrophoreses.
Analysis of early transcription start sites (TSSs)
To determine E1 mRNA TSS RNAs were reverse transcribed
using E1-speciﬁc primer R1 (position 1044–1070 nt, Fig. 2). First-
strand cDNAs were ampliﬁed by PCRs using the reverse primer R2
(position 536–557 nt) and three different forward primers: F1-
control primer located immediately upstream of P14 (position
7889–05 nt), F2-located two nucleotides downstream of P14
(position 16–37 nt) and F3-located two nucleotides downstream of
P97 (position 99–120 nt). The positions of primers are given
according to the HPV16 sequence in GenBank (accession number:
K02718.1). PCR products were analyzed by agarose gel electro-
phoreses, were photographed, excised, puriﬁed, and sequenced to
conﬁrm their identity.
To determine quantity of P14 and P97 transcripts ﬁrst-strand
cDNAs produced with random hexaprimers (Lytech, Russia) were
analyzed by TaqMan real-time PCR (CFX96, Bio–Rad) using F2, F3and R3 primer (position 206–227 nt) and two probes: position 58–
89 nt for P14- initiated transcripts and position 99–119 nt for the
sum of P14- and P97-initiated transcripts. The copy number of two
types of transcripts in a sample was determined in triplicates
using the standard curves constructed for each set of patient
samples. Then the number of P97 transcripts was calculated as the
difference between the numbers of P14 transcripts and summary
transcripts determined by the primers at P97 position. A set of
serial dilutions of SiHa DNA (on the basis of two copies HPV16 per
one cell) was used as PCR templates for the standard curves
(Meissner, 1999; Szuhai et al., 2000).Statistical analysis
Nonparametric Mann–Whitney U-test was used to compare dif-
ferences between quantities of transcripts produced from two differ-
ent promoters in CIN and cervical cancer samples. P-valueso0.05
were considered statistically signiﬁcant. All statistical procedures were
performed using GraphPad Prism 6 software.
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